MetaVia (MTVA) Expected to Announce Quarterly Earnings on Thursday

MetaVia (NASDAQ:MTVA) is expected to issue its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($2.06) per share for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 26, 2026 at 12:30 PM ET.

MetaVia Price Performance

MTVA opened at $1.55 on Tuesday. The company has a market capitalization of $3.41 million, a price-to-earnings ratio of -0.19 and a beta of 0.34. The business’s 50-day moving average price is $2.78 and its two-hundred day moving average price is $7.17. MetaVia has a 1 year low of $1.34 and a 1 year high of $23.10.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new stake in MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent quarter. Institutional investors and hedge funds own 1.37% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on MTVA. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Wall Street Zen cut shares of MetaVia from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, HC Wainwright lifted their price objective on shares of MetaVia from $12.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $36.50.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.